

**Diffusion-weighted imaging and predicting stroke outcome**

Hand et al. evaluated 82 patients with a broad range of stroke severities. The authors found that diffusion imaging (DWI) lesion characteristics did not predict functional outcome beyond key clinical variables (age, stroke severity). Hence, DWI is unlikely to reduce sample sizes in acute stroke trials assessing functional outcome.

see page 1159

*The editorial by Barber and Powers notes that accurate outcome prediction is helpful for discussions with patients and caregivers and in applying predictive models to the design and analysis of acute stroke treatment trials. MR DWI appears to be a less than ideal predictor of outcome following stroke. DWI is unlikely to reduce sample sizes for clinical trials in unselected stroke populations or to provide insight into the biologic effects of therapy.*

see page 1138

**Statin undertreatment among recent stroke survivors**

Ovbiagele et al. evaluated the frequency of statin use and achievement of national guideline target lipid goals among recent ischemic stroke survivors (in the VISP study), and found that less than half of guideline-eligible high vascular risk patients with ischemic stroke were treated according to recommended lipid goals.

see page 1164

*The editorial by Elkind and Benesch notes that it is possible that patients in this study ultimately did attain lower LDL levels than these numbers indicate. Moreover, there are no data on how many patients could not tolerate statins because of side effects, nor follow-up data on levels achieved over time. Nonetheless, these VISP data may reflect poor adherence to lipid guidelines among neurologists and others involved in stroke care, and are particularly worrisome as it is likely that those caring for patients in clinical trials have the most knowledge and experience in following vascular disease guidelines. They conclude that neurologists can no longer afford to leave preventive treatment of such patients to others.*

see page 1140

**Hyperdense artery sign on CT scan and thrombolysis**

Qureshi et al. found that IV thrombolysis significantly increased the rates of favorable outcomes at 90 days without any modifying effect of hyperdense artery sign on initial CT scans among 616 patients with ischemic stroke. Thus IV thrombolysis may be beneficial in this subgroup of patients.

see page 1171

**Hematoma growth related to outcome after ICH**

Davis et al. performed a meta-analysis of 218 placebo-treated patients with intracerebral hemorrhage. Hematoma growth (72.9% < 3 hours) independently determined mortality and functional disability, additional to baseline prognostic indicators such as age, level of consciousness, and hematoma volume.

see page 1175

**Functional effects of deep brain stimulation in PD**


Grafton et al. found that effective unilateral stimulation of the subthalamic nucleus in six patients with PD led to normalization of task-specific alterations of activity in motor areas and widespread reductions in compensatory overactivity.

see page 1192

*The editorial by Hershey and Mink discusses the use of functional imaging studies to study physiologic mechanisms of DBS. They review challenges facing the interpretation of functional imaging studies.*

see page 1142

**Long-term effect of selegiline on progression of PD**



Pålhagen et al. followed 140 patients with PD for 7 years in a double-blind study. Patients were initially treated with either selegiline or placebo. Later, when disability required, selegiline and placebo were replaced with levodopa. Selegiline significantly slowed the progression of disease disability and other signs and symptoms of PD.

see page 1200

---

### ■ **A three-protein biomarker panel for the diagnosis of ALS**

Pasinetti et al. identified a panel of three proteins whose content in the CSF is able to identify patients with ALS with 91% sensitivity and 97% specificity. A validation study confirmed that this biologic model correctly distinguishes patients with ALS from cases with peripheral neuropathy and healthy control subjects.

see page 1218

---

### ■ **Mycophenolate in dermatomyositis: Opportunistic infections**

Rowin et al. treated 10 patients with dermatomyositis with mycophenolate and corticosteroids. Although the combination was efficacious in 6/10, three patients developed opportunistic infections, leading to death in one.

see page 1245

---

### ■ **SPECT imaging of annexin V in AD**

Lampl et al. performed SPECT using radiolabeled annexin V, a marker of phosphatidylserine expression. Four of five patients with AD had multifocal cortical annexin V uptake, while all seven non-AD and six control patients had a normal SPECT.

see page 1253

---

### ■ **ICAM-1 polymorphism and risk for cervical artery dissection**

Longoni et al. describe an association between a SNP affecting the ICAM-1 gene and spontaneous cervical artery dissection, suggesting the possible involvement of inflammation in the pathogenesis of the disorder.

see page 1273

---

### ■ **Impaired cholinergic activity in FTDP with tau mutation**

In a PET study using <sup>11</sup>C-labeled N-methylpiperidin-4-yl acetate, Hirano et al. demonstrated decreased choline acetyltransferase (AChE) activity indicative of cholinergic impairment in two patients with FTDP-17 carrying the N279K tau mutation.

see page 1276

---

## NEUROLOGY INVITES "CLINICAL TRIALS RECRUITING" ANNOUNCEMENTS

*Neurology* now publishes a "Clinical Trials Recruiting" print and online section. This section is prominently displayed on the cover, in the Table of Contents, and on the *Neurology* Web site home page.

*Neurology* has the widest readership of any neurological journal, and *Neurology* online receives heavy traffic from the public. This online section has open access and is featured on the *Neurology* home page.

Line ads can be placed at no charge and display ads [full or 1/2 page] can also be placed for a fee. The ad must be IRB approved before submission. Contact [ctrecruiting@urmc.rochester.edu](mailto:ctrecruiting@urmc.rochester.edu) or click on "Clinical Trials Recruiting" on the home page [[www.neurology.org](http://www.neurology.org)] for more information.

# Neurology<sup>®</sup>

## April 25 Highlights

*Neurology* 2006;66;1136-1137

DOI 10.1212/01.wnl.0000217373.16002.d7

**This information is current as of April 24, 2006**

**Updated Information & Services**

including high resolution figures, can be found at:  
<http://n.neurology.org/content/66/8/1136.full>

**Permissions & Licensing**

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:  
[http://www.neurology.org/about/about\\_the\\_journal#permissions](http://www.neurology.org/about/about_the_journal#permissions)

**Reprints**

Information about ordering reprints can be found online:  
<http://n.neurology.org/subscribers/advertise>

*Neurology*® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright . All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

